BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase. 2007

Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.

Mycobacterium tuberculosis ribonucleotide reductase (RNR) is a potential target for new antitubercular drugs. Herein we describe the synthesis and evaluation of peptide inhibitors of RNR derived from the C-terminus of the small subunit of M. tuberculosis RNR. An N-terminal truncation, an alanine scan and a novel statistical molecular design (SMD) approach based on the heptapeptide Ac-Glu-Asp-Asp-Asp-Trp-Asp-Phe-OH were applied in this study. The alanine scan showed that Trp5 and Phe7 were important for inhibitory potency. A quantitative structure relationship (QSAR) model was developed based on the synthesized peptides which showed that a negative charge in positions 2, 3, and 6 is beneficial for inhibitory potency. Finally, in position 5 the model coefficients indicate that there is room for a larger side chain, as compared to Trp5.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012264 Ribonucleotide Reductases Ribonucleotide Reductase,Reductase, Ribonucleotide,Reductases, Ribonucleotide
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer

Related Publications

Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Design, synthesis, and evaluation of octahydropyranopyrrole-based inhibitors of mammalian ribonucleotide reductase.
December 2005, Bioorganic & medicinal chemistry letters,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
July 2007, Bioorganic & medicinal chemistry,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Peptide inhibitors of mammalian ribonucleotide reductase.
January 2005, Advances in enzyme regulation,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Synthesis and biological activity of cyclic peptide inhibitors of ribonucleotide reductase.
October 1999, Organic letters,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Ribonucleotide reductase inhibitors and future drug design.
August 2006, Current cancer drug targets,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Mycobacterium tuberculosis Transcription.
August 2022, Life (Basel, Switzerland),
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Toward a rational design of peptide inhibitors of ribonucleotide reductase: structure-function and modeling studies.
January 2001, Journal of medicinal chemistry,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
More potent linear peptide inhibitors of mammalian ribonucleotide reductase.
November 2004, Bioorganic & medicinal chemistry letters,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Johanna Nurbo, and Annette K Roos, and Daniel Muthas, and Erik Wahlström, and Daniel J Ericsson, and Torbjörn Lundstedt, and Torsten Unge, and Anders Karlén
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
December 2016, International journal of mycobacteriology,
Copied contents to your clipboard!